Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

NCT05488314 2026-03-13

METalmark

Phase 1/2 Active not recruiting

57 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05908734 2026-03-13

PolyDamas

Phase 1/2 Active not recruiting

71 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06120140 2026-03-13

COCOON

Phase 2 Recruiting

300 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07227025 2026-03-13

KaRAnaSa

Phase 1/2 Recruiting

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06083857 2026-03-11

PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer

Phase 1/2 Active not recruiting

3 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04538664 2026-02-25

PAPILLON

Phase 3 Active not recruiting

308 enrolled 12 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07392658 2026-02-06

AMICUTE

Phase 2 Recruiting

33 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04988295 2026-02-05

MARIPOSA-2

Phase 3 Active not recruiting

776 enrolled 13 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04487080 2026-02-04

MARIPOSA

Phase 3 Active not recruiting

1,074 enrolled 13 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05601973 2026-01-21

AMAZE-lung

Phase 2 Active not recruiting

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06667076 2026-01-16

COPERNICUS

Phase 2 Recruiting

480 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05845671 2026-01-14

Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations

Phase 1/2 Active not recruiting

12 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04965090 2025-12-18

A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

43 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06116682 2025-12-05

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Phase 2 Recruiting

88 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05299125 2025-10-01

AMIGO-1

Phase 2 Active not recruiting

54 enrolled

Thoracic

Metastatic Non-small Cell Lung Cancers

NCT06816992 2025-03-20

ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC

Phase 1 Recruiting

76 enrolled

Other solid neoplasmThoracic

Solid Tumors

NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Phase 1 Terminated

5 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Clinical Trials

Chrysalis-2

METalmark

PolyDamas

COCOON

KaRAnaSa

PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer

PAPILLON

AMICUTE

MARIPOSA-2

MARIPOSA

AMAZE-lung

COPERNICUS

Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations

A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

AMIGO-1

ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors